Limited efficacy of daratumumab in multiple myeloma with extramedullary disease
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
34247197
DOI
10.1038/s41375-021-01343-w
PII: 10.1038/s41375-021-01343-w
Knihovny.cz E-resources
- MeSH
- Antineoplastic Agents therapeutic use MeSH
- Clone Cells drug effects pathology MeSH
- Humans MeSH
- Survival Rate MeSH
- Multiple Myeloma drug therapy pathology MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Follow-Up Studies MeSH
- Plasma Cells drug effects pathology MeSH
- Prognosis MeSH
- Retrospective Studies MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antineoplastic Agents MeSH
- daratumumab MeSH Browser
- Antibodies, Monoclonal MeSH
Department of Biology and Ecology Faculty of Science University of Ostrava Ostrava Czech Republic
Department of Clinical Hematology University Hospital Brno Brno Czech Republic
Department of Nuclear Medicine University Hospital Ostrava Ostrava Czech Republic
Department of Pathology University Hospital Ostrava Ostrava Czech Republic
Hematology and Oncology Department Charles University Hospital Pilsen Czechia Czech Republic
Institute of Biostatistics and Analyses Ltd Brno Czech Republic
See more in PubMed
Dimopoulos MA, Moreau P, Terpos E, Mateos M-V, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5:e528. PubMed PMC
Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34:1–20. PubMed DOI
Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary disease in multiple myeloma—controversies and future directions. Blood Rev. 2019;36:32–39. PubMed DOI
Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99:360–4. PubMed DOI PMC
Gagelmann N, Eikema D-J, Iacobelli S, Koster L, Nahi H, Stoppa A-M, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018;103:890–7. PubMed DOI PMC
van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410–27. PubMed DOI
Jelinek T, Hajek R. Monoclonal antibodies—A new era in the treatment of multiple myeloma. Blood Rev. 2016;30:101–10. PubMed DOI
Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128:959–70. PubMed DOI
Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clinical Cancer Res. 2019;25:3176–87. DOI
Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW, et al. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia. 2020;34:938–41. PubMed DOI
Emran AA, Chatterjee A, Rodger EJ, Tiffen JC, Gallagher SJ, Eccles MR, et al. Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy. Trends Immunol. 2019;40:328–44. PubMed DOI
Varlet E, Ovejero S, Martinez A-M, Cavalli G, Moreaux J. Role of polycomb complexes in normal and malignant plasma cells. Int J Mol Sci. 2020;21:8047. DOI PMC
Piedra-Quintero Z. L., Wilson Z., Nava P., Guerau-de-Arellano M. CD38: an immunomodulatory molecule in inflammation and autoimmunity. Front Immunol. 2020; 11. https://doi.org/10.3389/fimmu.2020.597959 .
Beksac M. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma and soft-tissue plasmacytomas: Icaria-MM Subgroup Analysis. ASH, 2020 https://ash.confex.com/ash/2020/webprogram/Paper134727.html (accessed 11 Mar2021).
Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34:1875–84. PubMed DOI PMC
Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
Identification of patients at high risk of secondary extramedullary multiple myeloma development
Natural Killer Cells in the Malignant Niche of Multiple Myeloma
